Skip to main navigation Skip to search Skip to main content

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (CHARM)

Project: Research

Project Details

StatusFinished
Effective start/end date02/2/21 → 05/30/25

Funding

  • Biogen MA Incorporated: $31,465.00